@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix nkg: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "Off-label (non-FDA-approved) uses for Lorazepam include rapid tranquilization of the agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting (adjunct or breakthrough), as well as psychogenic catatonia.";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:has_population_context sub:cohort;
bl:provided_by "NeuroDKG";
bl:publications ;
bl:relation nkg:OffLabelIndication .
sub:cohort rdfs:label "Adults";
bl:category bl:Cohort .
bl:category bl:Drug .
bl:category bl:Disease .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
npx:hasSignature "CqKUmQjVJIy7d4BKbZtNI2P7RJ7WipUH00kRQn8Q0lNXYQqs56FJ3/IWYh5nohxla5/gp0KS6QX8jEvLukT9cZOjCOGfhDF8o4CSBp+Ov7WicgIVnEB9zyVtUg8li9kZFmn0juBKtZ7P/4V9MBsitvpX7IPCCB3W4UO83JAA588=";
npx:hasSignatureTarget this: .
this: ns1:created "2021-03-22T10:56:37.839+01:00"^^xsd:dateTime;
ns1:creator orcid:0000-0002-7641-6446;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}